|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 nicotinic acetylcholine receptor1Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Emory University School of Medicine, Atlanta; and 2Atlanta Veterans Affairs Medical Center, Decatur, Georgia
Submitted 25 January 2007 ; accepted in final form 31 May 2007
| ABSTRACT |
|---|
|
|
|---|
7 nicotinic acetylcholine receptors, which mediate many of the biological effects of nicotine, is highest in pseudoglandular stage lungs compared with lungs at later stages. We then studied the effects of nicotine in the explant model and found that nicotine stimulated lung branching in a dose-dependent fashion.
-Bungarotoxin, an antagonist of
7 nicotinic acetylcholine receptors, blocked the stimulatory effect of nicotine, whereas GTS-21, a specific agonist, stimulated branching, thereby mimicking the effects of nicotine. Explants deficient in
7 nicotinic acetylcholine receptors did not respond to nicotine. Nicotine also stimulated the growth of the explant. Altogether, these studies suggest that nicotine stimulates lung branching morphogenesis through
7 nicotinic acetylcholine receptors and may contribute to dysanaptic lung growth, which in turn may predispose the host to airway disease in the postnatal period. lung growth; nicotinic receptors
Although the composition of tobacco smoke is complex, nicotine is recognized as a major component that traverses the placental barrier. Spindel and colleagues (24, 26) showed that chronic nicotine exposure in nonhuman primates results in alterations in collagen deposition around large airways and blood vessels in the fetus, increases in collagen mRNA expression in airway fibroblasts and smooth muscle cells, larger air spaces with less surface area, and increased type II cells. When lung function was examined, they found that these nicotine-induced alterations were associated with airflow limitation (25). These and related studies suggest that nicotine may affect lung development, thereby promoting airway dysfunction in the postnatal period. However, the mechanisms responsible for the effects of nicotine in fetal lungs and how they may affect lung development in utero remain unelucidated.
We postulated that nicotine affects lung branching morphogenesis, the process responsible for the formation of the primitive tubules that later become the airway tree, through effects on
7 nicotinic acetylcholine receptors (nAChRs). These ligand-gated ion channels represent the most common homomeric form of nAChRs in the body, and although their expression is highest in the central nervous system and muscle, they have been detected in fetal and adult lungs and in other organs (4).
7 nAChRs mediate the stimulatory effects of nicotine on matrix expression in lung fibroblasts (22).
7 nAChRs are also under transcriptional regulation by thyroid transcription factor (TTF-1), a transcription factor essential for the development of the lung (17). Multiple other functions of
7 nAChRs in lung cells have been reported, including bronchial epithelial cells, where
7 nAChRs appear to be involved in regulating cell-cell interactions, adhesion, and motility (31). Blockade of
7 nAChRs inhibits angiogenesis and endothelial network formation through VEGF-dependent pathways (11).
Thus, using embryonic murine lung explants, we set out to explore the role of nicotine in lung branching morphogenesis. We found that nicotine stimulates lung branching through
7 nAChRs, which are highly expressed during the pseudoglandular stage of lung development.
| METHODS |
|---|
|
|
|---|
7 nAChR-deficient strain Chrna7tm1Bay, also in the C57BL/6J strain, obtained from Jackson Laboratories (Bar Harbor, ME). All animal protocols were approved by the Emory University Institute Animal Care and Use Committee.
Reagents.
Nicotine and the
7 nAChR antagonist
-bungarotoxin were obtained from Sigma Chemicals (St. Louis, MO). The
7 nAChR agonist GTS-21 was generously donated by Dr. Richard Papke from the University of Florida (Gainesville, FL) through Taiho Pharmaceuticals in Japan. The anti-
7 nAChR rabbit antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The Vectastain ABC kit obtained from Vector Laboratories (Burlingame, CA) was used for immunohistochemistry. Blocking solution for immunohistochemistry was acquired from DakoCytomation California (Carpinteria, CA). For lung explant cultures, the DMEM was purchased from Mediatech (Herndon, VA), and the fetal bovine serum was purchased from Atlanta Biologicals (Norcross, GA). All other reagents were obtained from Sigma Chemicals (St. Louis, MO) or Fisher Scientific (Hampton, NH) unless otherwise specified.
Organ culture of murine lung explants and quantification of branching morphogenesis.
The murine lung explant model has been previously described (1). Briefly, timed pregnant CD57BL/6J mice were killed to obtain embryos at embryonic day 11(E11). Day 0 was determined by the presence of a cervical plug. Lung rudiments were removed from the embryos in sterile PBS, placed on Costar Transwell plates, and cultured at the air-medium interface using DMEM-10% FBS. The cultures were incubated under 5% CO2 at 37°C for 5 days, and the medium was changed daily. Nicotine (1 µM), the
7 nAChR antagonist
-bungarotoxin (5 nM), and the
7 nAChR agonist GTS-21 (3 µM) were added to medium at the time the cultures were established and with each subsequent medium change. Branching was determined by counting the total number of branching clefts each day at the same time for 5 days. Branching clefts were visualized in whole mount by transillumination on a dissecting microscope.
Statistical analysis of explant culture experiments. At least three to five lungs were included for each experimental condition, and all experiments were performed at least three times. Experimental results were consistent between multiple repeat experiments. Data from representative experiments were chosen for presentation in RESULTS; hence, the data are presented as means ± SD. Statistical significance of the difference in means was determined using the t-test method (criterion for significance, P < 0.05).
DNA content determination. DNA content was estimated using DNA fluorometry as previously described (1). After explants were cultured for 5 days, they were placed in 10x TNE buffer (100 mM Tris, 10 mM EDTA, 2 M NaCl, pH 7.4) and homogenized. Using Hoechst dye 33258, which binds double-stranded DNA and fluoresces at 465 nm, we estimated total DNA content per lung explant by following standard curve calculations generated using calf thymus DNA as the standard. A representative experiment was chosen for presentation in RESULTS.
Immunohistochemistry.
Timed pregnant CD57BL/6J mice were killed at E11, E13, E15, E17, E19, and postnatal day 1. Lung rudiments were obtained from the embryos, fixed in 4% paraformaldehyde, and embedded in paraffin blocks. Sections (5 µm) were deparaffinized and rehydrated in graded alcohols. Endogenous peroxidase activity was blocked using 3% H2O2. Sections were washed in 1x TBS-0.05% Tween and blocked using antibody diluent and blocking solution (DakoCytomation) followed by overnight incubation at 4°C with 1:200 dilution of the anti-
7 nAChR rabbit antibody (Santa Cruz Biotechnology). Sections were incubated with appropriate biotinylated secondary antibody according to materials and protocol provided by the Vectastain ABC kit (Vector Laboratories). Diaminobenzidine was used for chromogenic visualization (Vector Laboratories).
Semiquantitative bioluminescent RT-PCR.
The determination of mRNA levels was done using a semiquantitative bioluminescence-based RT-PCR assay as previously described (15). RNA was extracted from E11, E13, E15, E17, E19, and postnatal day 1 lungs by using RNA-Bee reagent (Tel-Test, Friendswood, TX). E11 and E13 lungs were pooled from entire litters because of the size of individual lungs; each litter was considered a single sample. Biotinylated PCR primers and probes for mouse
7 nAChR were synthesized by Sigma-Genosys Biotechnologies (The Woodlands, TX). Primers and probes for
7 nAChR were synthesized based on GenBank published sequences. They were as follows: 5'-GTAACCATGCGCCGTAGG-3', 3'-CCGAGGCTTGTGCTGAC-5', and probe 3'-GGTGCTGGCGAAGTACTG-5'.
Reverse transcription of mRNA was done using the Promega Access RT-PCR kit (Promega, Madison, WI) with 1 µg of RNA sample and 1 µl (200 units) of SuperScript III RT (Invitrogen, Carlsbad, CA) (see manufacturer's protocol). The first-strand cDNA synthesis reaction was carried out at 50°C for 1 h using 0.5 µl (0.5 units) of Taq DNA polymerase (Invitrogen). The thermal cycling parameters consisted of 95°C (3 min); 25 cycles of 94°C (1 min), 54°C (0.5 min), and 72°C (1 min); and a final extension at 72°C (5 min).
After amplification, the biotinylated PCR products were denatured, neutralized, and added to streptavidin-coated plates (Roche, Indianapolis, IN). To each well, we added 100 µl of hybridization buffer (62.5 mM Na2HPO4, 94 mM citric acid, 15 mM sodium azide, 0.0625% BSA, 94 mM NaCl, 0.0125% Tween 20, and 10 mM MgCl2) containing 2 ng of the digoxigenin-labeled probes. Hybridization was done for 2 h at 42°C. After hybridization, the plates were washed, and 100 µl of assay buffer (25 M Tris base, 10 mM EDTA, 0.15 M KCl, 15 mM sodium azide, and 2 mg/ml BSA) containing 1 µl of anti-digoxigenin aequorin conjugate (AquaLite Chemicon, Temecula, CA) was added to each well. The plates were incubated for 30 min at room temperature and washed. Luminescence was measured on a Luminoskan Ascent microtiter plate luminometer (ThermoLabsystems, Franklin, MA) after triggering with 0.1 M calcium. Results were plotted as relative fluorescent units. Standardization reactions were done for the hypoxanthine phosphoribosyltransferase (HPRT) gene with probes synthesized based on GenBank published sequences. They were as follows: 5'-TGGTGGAGATGATCTCTC-3', 3'-CATCAACAGGACTCCTCG-5', and probe 3'-GAGAGGTCCTTTTCACCA-5'. RT-PCR experiments were repeated in triplicate, and the data are means ± SE.
Quantitative real-time PCR.
Quantitative real-time PCR was done to determine mRNA expression in an additional manner as previously described (16). Total cellular RNA was extracted from lung explant cultures and fetal lungs obtained at selected gestational time points (E11, E13, E15, E17, E19), and reverse transcription reactions were performed as described above. Real-time PCR reactions were set up by adding the following reagents to Smart Cycler reaction tubes (Sunnyvale, CA): 5 mM MgCl2, 0.2 µM forward primer, 0.2 µM reverse primer, 10x Master Mix (SYBR Green JumpStart Taq ReadyMix for quantitative PCR, Sigma), and template cDNA (500 ng total). Primers for
7 nAChR, fibronectin, and HPRT were synthesized based on GenBank published sequences.
7 nAChR forward and reverse primers were 5'-GTAACCATGCGCCGTAGG-3' and 3'-CCGAGGCTTGTGCTGAC-5,' respectively. Fibronectin forward and reverse primers were 5'-CTGTGACAACTGCCGTAG-3' and 5'-ACCAAGGTCAATCCACAC-3', respectively. HPRT forward and reverse primers were 5'-TGGTGGAGATGATCTCTC-3' and 3'-GAGAGGTCCTTTTCACCA-5', respectively. Samples were briefly centrifuged and processed using the following cycle program with the Cepheid Smart Cycler: holding at 95°C for 600 s, followed by 40 cycles at temperatures of 95°C for 15 s, 68°C for 30 s (with Optics on), and 72°C for 30 s. Results of the log-linear phase of the growth curve were analyzed using the mathematical equation of the second derivative, and relative quantification was performed using the 2–
CT method (13a).
| RESULTS |
|---|
|
|
|---|
7 nAChRs in developing murine lungs.
We began by exploring the distribution and expression of
7 nAChRs in developing lungs using semiquantitative RT-PCR, quantitative real-time PCR, and immunohistochemistry. RT-PCR and quantitative real-time PCR studies revealed
7 nAChR mRNA and protein at all stages of lung development, but
7 nAChR mRNA expression was highest in pseudoglandular stage lungs (E13–E15) and decreased by E17 (Fig. 1A).
7 nAChR protein was identified on both epithelial and mesenchymal cells, particularly around the primitive airways (Fig. 1, B–D), but not all cells stained positive. Staining for the
7 nAChR protein was consistent with higher expression of
7 nAChR at E11 through E15 (Fig. 1, B–D).
|
7 nAChRs.
To test the effects of nicotine on lung branching morphogenesis, we used the lung explant model. Lungs obtained at E11 were cultured with varying concentrations of nicotine. In this system, nicotine was found to stimulate branching, and this effect was most noticeable at days 4 and 5of culture (Fig. 2, A and B). Despite the increased number of branches, the pattern of branching seemed equivalent between groups, and the morphology of the terminal buds was not different (Fig. 2A). The increase in branching occurred in a dose-dependent fashion, with more branches in 5 µM nicotine than in 1 µM nicotine (data not shown). Of note, the nicotine-treated lungs appeared larger than their untreated counterparts, suggesting an effect on explant growth (see below).
|
-bungarotoxin, a selective antagonist of
7 nAChRs (Fig. 2B). Culture with 5 nM
-bungarotoxin alone in the medium did not impair branching. To further test the role of
7 nAChRs, we treated lung explants with GTS-21, an
7 nAChR agonist also known as DMBX. Like nicotine, GTS-21 stimulated lung branching (Fig. 2C).
To confirm our hypothesis that
7 nAChRs mediate the effects of nicotine on branching, we obtained lung rudiments for explant culture from
7 nAChR-deficient mouse embryos (Jackson Laboratories) and exposed them to nicotine. After 5 days in culture, the explants from
7 nAChR-deficient mouse embryos did not demonstrate a stimulation in branching with nicotine treatment similar to that seen in wild-type CD57BL/6J mice. The untreated lungs from
7 nAChR-deficient embryos appeared to have slightly fewer branches than the wild-type at the end of 5 days, although the difference was not statistically significant. The branching pattern appeared similar (Fig. 3).
|
-bungarotoxin, the antagonist was not as effective in diminishing growth as it was in blocking branching.
|
|
| DISCUSSION |
|---|
|
|
|---|
Nicotine is a well-studied component of tobacco smoke that is known to cross the placental barrier to the fetal circulation and has been implicated as an etiologic agent in adverse fetal events related to environmental tobacco smoke (13). Although a link between exposure to nicotine alone during the prenatal period and airway dysfunction has not been established in humans, several studies have suggested a role for nicotine in other animals. For example, Sekhon et al. (25) showed that fetal monkeys exposed to nicotine in the prenatal period have altered pulmonary function similar to that seen in infants and children, including decreased forced mid-expiratory flow and increased airway resistance. In addition to the physiological differences, there were also histological changes in the lungs exposed to prenatal nicotine. Specifically, nicotine-treated animals exhibited lungs with less alveolar surface area available for gas exchange as a consequence of larger air spaces. The composition of the matrix of the airway wall was also different, particularly the cartilaginous airways, which showed a significant increase in the amount of collagen deposition in the airway wall (24, 26). These findings illustrate that nicotine potentially alters the normal pattern of airways and parenchymal development, which may subsequently impact pulmonary function.
In view of the above information, we hypothesized that nicotine affects lung branching morphogenesis, thereby disrupting airway formation in ways that do not prevent further lung development but that might predispose the host to airway dysfunction after birth. To test this, we exposed pseudoglandular stage murine lung explants to nicotine and evaluated for branching. We used 1 µM nicotine in the majority of our experiments to better approximate physiological concentrations seen by fetuses of smoking mothers. It has been reported that fetuses are exposed to higher concentrations of nicotine than their mothers. In the fetal serum, the concentration of nicotine ranges from 3 nM to 0.1 µM (14). Our studies show that nicotine stimulated branching, and this effect was most evident at culture days 4 and 5. These findings are similar to those described by Wuenschell et al. (30), who found that nicotine stimulated branching and induced the expression of surfactant proteins A and C, suggesting an effect on epithelial cell differentiation and perhaps lung maturation. Of note, the dichotomous and monochotomous branching pattern of nicotine-treated lung explants did not differ from that of untreated explants, suggesting that nicotine may accelerate branching by an early induction of the same cellular processes involved in branching morphogenesis seen in the normal fetal lung such as fibroblast growth factor-10, bone morphogenetic protein-4, and Sonic hedgehog signaling (2).
We also tested the role of
7 nAChRs in nicotine-induced lung branching.
7 nAChRs are present in the fetal lung in a developmentally dynamic manner, and its gene transcription has recently been found to be regulated by TTF-1, an essential transcription factor for the initiation of lung morphogenesis (17). Prenatal nicotine exposure also increases expression of
7 nAChRs around airways (24). Using semiquantitative RT-PCR, we found that mRNA expression of
7 was highest at E13–E15, followed by a decrease at E17. This was confirmed by real-time PCR. Our own immunohistochemical studies showed expression of
7 protein in epithelial and mesenchymal cells between E11 and E13.
Since the highest detectable expression of
7 nAChRs is during the pseudoglandular stage of lung development (E11–E15), when branching morphogenesis takes place, one can infer a potential role of
7 nAChRs during branching. That is exactly what we found. Of note, the antagonist of
7 nAChRs, the snake venom
-bungarotoxin, inhibited nicotine-induced lung branching in our system. Furthermore, a specific agonist of
7 nAChRs, GTS-21, stimulated branching, thereby mimicking the effects of nicotine. Finally, lung explants deficient in
7 nAChRs were not found to respond to nicotine stimulation during branching morphogenesis. Interestingly, mice deficient in
7 nAChRs do appear to have normal lung development, indicating that
7 nAChRs are not essential for branching morphogenesis, but this needs to be confirmed with careful morphometric and functional studies. Independently, our data suggest that perturbing the normal expression and signaling pathways of
7 nAChRs, particularly by nicotine, can affect branching.
We then turned our attention to organ growth. Since lung explants cultured in nicotine appeared larger in two-dimensional size, we questioned whether nicotine affected growth. Indeed, we found that nicotine stimulated overall growth. This is not surprising in view of reports linking organ growth with branching potential (21). Of note, we were unable to entirely block that growth with a specific
7 nAChR antagonist,
bungarotoxin. Furthermore, growth in the
7 nAChR-deficient explants was not different between the untreated and nicotine-treated conditions. Thus
7 nAChRs play an important role in branching morphogenesis, but their role in regulating growth needs to be explored further.
Although branching morphogenesis is a complex program with multiple epithelial and mesenchymal interactions, we attempted to look at one morphogen in particular: fibronectin. Fibronectin is usually mesenchymal in origin but also has been described in the epithelium during branching morphogenesis (22a). Fibronectin expression in fetal lung fibroblasts already has been shown to increase with exposure to nicotine through
7 nAChR-mediated signals (22). We found that both nicotine treatment of lung explant cultures in vitro and prenatal nicotine exposure in vivo results in increased fibronectin expression in the pseudoglandular stage lung. Thus increasing fibronectin expression may be one way that prenatal nicotine exposure increases branching.
Our results showing nicotine stimulation of branching morphogenesis and stimulation of growth may provide an explanation to the decreased pulmonary function found in offspring with prenatal nicotine exposure. Many of the decreased flows observed in monkeys treated with nicotine likely reflect an airway, rather than a parenchymal, etiology, since there was increased deposition of collagen around the airways (26). It is possible that changes in the structure of conducting airways alone can result in overall decreased airflow with increased resistance. Since branching morphogenesis creates the template for conducting airway formation, any alteration in branching may also have an impact on the number and size of conducting airways that can result in abnormal expiratory flows. In our model, prenatal nicotine exposure may actually result in greater total airway length based on unpublished data using stereological analysis.
The dissociation between growth and branching raises the concept of dysanaptic growth. Dysanaptic growth refers to the disproportionate growth between conducting airway and alveolar parenchyma first described to explain variability in expiratory flow volume curves (9). In our lung explant model, branching mediated through the
7 nAChR appears to be dissociated from the overall growth, suggesting that dysanaptic growth is occurring in this pathway. Simply having dysanaptic growth may lead to alterations in lung function studies. Some epidemiological studies have shown that infants exposed to prenatal tobacco smoke have different physiological lung function irrespective of airway hyperresponsiveness (28). Dysanaptic growth also has been proposed as a potential mechanism that alters lung function in other models involving different growth conditions (6, 23). The abnormal lung function associated with prenatal nicotine exposure may be a consequence of dysanaptic growth by changing branching morphogenesis without an equal change in parenchymal growth.
In summary, our results suggest that nicotine directly impacts branching morphogenesis during the pseudoglandular stage through effects on
7 nAChRs. Nicotine's effects on branching morphogenesis may be partially mediated by the stimulation of fibronectin expression, but this needs to be explored further. This interaction may explain why some infants and children exposed to prenatal environmental tobacco smoke demonstrate abnormal pulmonary function. Our studies continue to emphasize the importance of eliminating environmental tobacco smoke exposure for expectant mothers, infants, and children, as well as raising the question whether an alternative to nicotine replacement therapy for pregnant smokers is needed.
| GRANTS |
|---|
|
|
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|

CT method. Methods 25: 402–408, 2001.[CrossRef][Web of Science][Medline]
5
1-integrin receptors in human monocytic cells in a protein kinase C-dependent fashion. Am J Physiol Lung Cell Mol Physiol 287: L239–L249, 2004.
7 nicotinic acetylcholine receptor by thyroid transcription factor-1 and early growth response factor-1 during murine lung development. J Biol Chem 280: 32548–32554, 2005.
7 nicotinic receptor expression and alters fetal lung development in monkeys. J Clin Invest 103: 637–47, 1999.[Web of Science][Medline]
7 nicotinic acetylcholine receptors. Am J Respir Cell Mol Biol 26: 31–41, 2002.This article has been cited by other articles:
![]() |
J. Roman and M. Koval Control of Lung Epithelial Growth by a Nicotinic Acetylcholine Receptor: The Other Side of the Coin Am. J. Pathol., November 1, 2009; 175(5): 1799 - 1801. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Y. Lopez-Hernandez, J. S. Thinschmidt, G. Zheng, Z. Zhang, P. A. Crooks, L. P. Dwoskin, and R. L. Papke Selective Inhibition of Acetylcholine-Evoked Responses of {alpha}7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists Mol. Pharmacol., September 1, 2009; 76(3): 652 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Maritz Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring Therapeutic Advances in Respiratory Disease, August 1, 2009; 3(4): 193 - 210. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |